Table 45Interstitial lung disease in patients with rheumatoid arthritis treated with oral DMARDs

StudyStudy Design
N
Duration
Study PopulationDrugResultsQuality Rating
Suissa et al., 2006217Retrospective cohort (claims data)
62,734
5 years
RA diagnosis, on DMARDMTX, LEF, biologics, traditional DMARDsRisk of interstitial lung disease in LEF compared with other DMARDs: OR, 1.9 (95% CI, 1.1 to 3.6). No elevation noted in LEF pts with no history of MTX or no history of interstitial lung diseaseFair
*Wolfe et al., 2007228Prospective cohort
17,598
Up to 3.5 years
RA pts in the National Databank for Rheumatic DiseasesMTX, LEF, HCQ, SSZNo significant association between current and past MTX, LEF, HCQ, and SSZ use and hospitalization for interstitial lung disease.Fair
*

New study added since last review.

CI =confidence interval; DMARD = disease-modifying antirheumatic drug; HCQ = hydroxychloroquine; LEF = leflunomide; MTX = methotrexate; OR = odds ratio; Pts = patients; RA = rheumatoid arthritis; SSZ = sulfasalazine

From: Results

Cover of Drug Therapy for Rheumatoid Arthritis in Adults: An Update
Drug Therapy for Rheumatoid Arthritis in Adults: An Update [Internet].
Comparative Effectiveness Reviews, No. 55.
Donahue KE, Jonas DE, Hansen RA, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.